Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data.
about
Treating osteoporosisPotential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.Associations between the 2007 Medicare reimbursement reduction for bone mineral density testing and osteoporosis drug therapy patterns of female Medicare beneficiaries.Bone mineral density testing: too much of a good thing?Update in women's health for the general internist.Measuring low-value care in Medicare.Alendronate and raloxifene therapy in the early period after hip fractureBisphosphonate therapy: when not to monitor BMD.Bisphosphonates: forever or 5 years and stop?Monitoring drug therapy.Understanding Referral Patterns for Bone Mineral Density Testing among Family Physicians: A Qualitative Descriptive Study.BMD screening in older women: initial measurement and testing intervalChanges in Low-Value Services in Year 1 of the Medicare Pioneer Accountable Care Organization ProgramClinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition).Low-Value Service Use in Provider Organizations.Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture® Best Practice Framework tool.Incidence and Predictors of Repeat Bone Mineral Densitometry: A Longitudinal Cohort Study.The effect of weight and weight change on the long-term precision of spine and hip DXA measurements.The potential value of monitoring bone turnover markers among women on alendronate.A comparison of case-finding strategies in the UK for the management of hip fractures.Treatment failure in osteoporosisGoal-directed therapy in osteoporosis
P2860
Q26747363-0B974E0A-0377-4656-A136-43149252261FQ31065032-EEB9523C-B581-48A9-B09A-BFD4F2B61686Q33831291-3E49B302-439F-49C3-B9FC-210BF5A13114Q34406226-9E28E76A-5DCE-4766-84A6-0E45DDF573EAQ34482554-050C0CFC-45AA-485F-84EC-71F47EF61C0EQ34562997-614B97D0-1F9F-460F-967B-E7A45800535DQ35022755-31D7A144-4193-4925-BD82-063D338A5049Q35247135-E6C670BB-C6C0-4E36-92FA-61A12758E9E9Q35601553-6A53D82B-C362-4249-B7CD-0AC927B8666FQ36081472-4B1F147F-B3EB-472A-87BF-D0391F1F2E75Q36557064-C16495D1-1C41-4418-8A11-EF10E1FA4B23Q36630230-3E6C364E-8B8F-4597-942E-7F5961570645Q37055298-FC7A7467-C201-4ACB-A112-0BD0E1E727FFQ37731292-73BAAD71-0904-4AC4-8BEE-268BE5D6617DQ38059153-609EC088-4D68-418F-822C-6EC802B84189Q39175606-5B308A45-623A-40C9-80A9-47AA19DFF7D8Q41674252-38B64857-408B-4956-A32B-E78F46960007Q46381504-A234CA9F-BF84-4409-AC7B-DDDCB22EE115Q46681121-DF7711D3-C376-4819-B1C7-8B29D2E66ECEQ51170565-F045D017-B4C4-4A93-86D7-FE45AE15933FQ51453264-63526FD8-06EE-4F17-99FE-D1C9E5C2E655Q57417008-560ABE01-BEB5-4562-B235-12B31B7655C4Q57711404-7350FC02-006A-4B3A-AD26-0C4C254598BE
P2860
Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Value of routine monitoring of ...... ondary analysis of trial data.
@ast
Value of routine monitoring of ...... ondary analysis of trial data.
@en
type
label
Value of routine monitoring of ...... ondary analysis of trial data.
@ast
Value of routine monitoring of ...... ondary analysis of trial data.
@en
prefLabel
Value of routine monitoring of ...... ondary analysis of trial data.
@ast
Value of routine monitoring of ...... ondary analysis of trial data.
@en
P2093
P2860
P50
P356
P1433
P1476
Value of routine monitoring of ...... condary analysis of trial data
@en
P2093
Douglas C Bauer
Katy J L Bell
P2860
P356
10.1136/BMJ.B2266
P407
P577
2009-06-23T00:00:00Z